Oncologists raised alarms about chemotherapy drug shortages, warning that persistent constraints on manufacturing and pricing incentives can force substitutions and workarounds. A report cited shortages of carboplatin, cisplatin, oxaliplatin, and ifosfamide, with U.S. FDA data indicating ifosfamide injection formulations may remain in shortage until at least October 2026. Clinicians described operational responses including prioritizing regimens for patients with curative intent, using alternatives when available, and adjusting dosing toward lower ends of recommended ranges. The report also quoted clinicians warning that sensitive, curable cancers could become harder to treat without reliable access to specific generics. The issue is presenting as a direct patient-care risk in oncology, not a theoretical supply-chain concern.